16 September 2024 in Radiotherapy and Oncology
Treatment modalities for patients with brain metastases consist of surgery, radiotherapy, and systemic treatments such as immunotherapy and targeted therapy. Although much is known about local control of brain metastases after radiotherapy and surgery alone, more understanding is needed of the additional effect of new systemic treatments. Our study presents real-world data about the combined effects of different local and systemic treatment strategies on local response of irradiated brain metastases. We performed a retrospective consecutive cohort study of patients that presented with brain metastases in our institution between June 2018 and May 2020, reporting the impact of radiotherapy alone versus radiotherapy combined with systemic treatment on local control of irradiated brain metastases and toxicity. Chemotherapy and targeted therapy were temporarily discontinued around irradiation. 262 consecutively treated patients were included in the study. Median time to local failure of irradiated brain metastases was 18 months (IQR 9-34), median overall survival was 20 months (IQR 10-36). 211 (81 %) patients received systemic treatment. Patients with breast cancer had a worse local control (HR 2.3, 95 % CI 1.0-5.0, p = 0.038), as did patients without any systemic treatment (HR 2.1, 95 % CI 1.1-4.3, p = 0.034). Symptomatic radiation necrosis occurred in 36 (14 %) patients. A diameter > 2.5 cm was associated with a higher risk of radiation necrosis. No association was found between systemic treatment in combination with local radiotherapy and symptomatic radiation necrosis. Patients who received any form of systemic treatment had better local control after stereotactic radiosurgery for brain metastases. We did not find an association between systemic treatment and the incidence of radiation necrosis.
8 September 2025 in Radiotherapy and Oncology
Staged Gamma Knife radiosurgery (SGKRS) delivers high-dose radiotherapy to large brain metastases (BM) in two or three fractions with a time interval of several weeks. Various systemic treatments have also demonstrated favorable intracranial responses. Therefore, the outcome of patients undergoing radiosurgery and systemic treatment for large BM is of high interest but unknown. A retrospective cohort study was conducted on patients with large BM treated with SGKRS without previous local treatment directed to the brain. The primary outcome measure was the probability of intracranial local control at 12 months, calculated by the Kaplan-Meier method. Univariate and multivariate Cox regression analyses were performed to identify variables associated with intracranial local control. 295 patients were included. Intracranial local control probability at 12 months was 83 % and overall survival at 12 months was 39 %. In the multivariate Cox regression analysis, receiving any type of concurrent or adjuvant systemic treatment (adjusted hazard ratio [aHR] 0.30, 95 % confidence interval [CI] 0.15-0.61) and volume reduction between the first and second fraction (aHR 0.99, 95 % CI 0.98-0.998) were significantly associated with better intracranial local control. Larger total volume of all treated BM (aHR 1.02, 95 % CI 1.01-1.04) was significantly associated with worse intracranial local control. The probability of symptomatic cerebral radiation necrosis at 12 months was 26 %. SGKRS results in high local control, with further improvement when systemic treatment is administered. However, overall survival remains limited, highlighting the importance of adequate patient selection.